BioSpace News Archive

HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancer

ProKidney Corp. announced the appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization.

AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio’s StemoniX subsidiary.

Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th 2023.

CytomX Therapeutics, Inc. today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO).

Travere Therapeutics, Inc. (NASDAQ: TVTX) and Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that they have entered into a definitive agreement for the sale of Travere’s bile acid product portfolio that includes Cholbam® (cholic acid) and Chenodal® (chenodiol), two medications addressing rare diseases in high-need settings.

Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tools for the job, acquired Blacktrace Holdings.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, education and government, advanced technologies and applied materials industries, announced plans to relocate and significantly expand the company’s Bridgewater, N.J. Innovation Center.

Lantern Pharma Inc. today announced that the Company will participate and present at four upcoming conferences.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, August 3, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company’s second-quarter 2023 operating and financial results.